Biosight Ltd. Revenue and Competitors

Lod,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Biosight Ltd.'s estimated annual revenue is currently $1.7M per year.(i)
  • Biosight Ltd.'s estimated revenue per employee is $155,000

Employee Data

  • Biosight Ltd. has 11 Employees.(i)
  • Biosight Ltd. grew their employee count by -8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$15.3M99-49%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.5M29-6%N/AN/A
#10
$9.6M62-7%N/AN/A
Add Company

Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders. Biosight's lead product, BST-236 (aspacytarabine), is an innovative proprietary anti-metabolite which addresses unmet medical needs by enabling high-dose chemotherapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a Phase 2b for first-line treatment of acute myeloid leukemia (AML), following completion of a Phase 1/2a study which demonstrated tolerability with promising efficacy in the challenging population of AML patients unfit for standard of care chemotherapy. A Phase 2 study in relapsed/refractory AML and myelodysplastic syndrome (MDS) will be launched in 2020 under a collaboration agreement recently signed with the European cooperative group, GFM.

keywords:N/A

N/A

Total Funding

11

Number of Employees

$1.7M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.3M15-29%N/A
#2
$7.8M5417%N/A
#3
$17.2M5814%N/A
#4
$27M100-12%N/A
#5
$3.5M10935%N/A